title: Levamisole in rheumatoid arthritis. Final report on a randomised double-blind study comparing a single weekly dose of levamisole with placebo. Multicentre Study Group.
abstract: The therapeutic effect of a single weekly dose of levamisole in patients with rheumatoid arthritis was compared with placebo for 6 months in a 13-centre double-blind controlled study. 281 patients with classic or definite rheumatoid arthritis and active disease were evaluated. A single weekly dose of 150 mg levamisole was superior to placebo in controlling disease activity. A single weekly dose of 50 mg levamisole had an intermediate effect. Adverse reactions occurred in approximately 40% of the patients with 150 mg levamisole and in approximately 20% of the patients with 50 mg levamisole or placebo. In comparison with the classical dosage schedule of levamisole (150 mg on 3 consecutive days each week) a single weekly dose of 150 mg levamisole was found to be slightly less effective but much better tolerated.
mesh_terms: D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007978:Levamisole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011897:Random Allocation
chemical_list: D007978:Levamisole